Top

Published in:

19-01-2024 | Gynecologic Cancer | ASO Author Reflections

ASO Author Reflections: To Test or Not to Test: How Do We Decide the Optimal Site for Organoid Generation in Patients with Metastatic Disease?

Authors: Shannon N. Radomski, MD, Jonathan B. Greer, MD, Fabian M. Johnston, MD, MHS, Andrew J. Ewald, PhD

Published in: Annals of Surgical Oncology | Issue 4/2024

Excerpt

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is a treatment option for select patients with peritoneal metastases (PM). Despite its use for more than 30 years, little progress has been made in decreasing the rates of recurrence following CRS/HIPEC. One potential contributor to recurrence, which has been demonstrated in patients with metastatic ovarian cancer, is chemotherapeutic drug response heterogeneity between different metastatic sites.¹ …

Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25:838–49. https://doi.org/10.1038/s41591-019-0422-6.CrossRefPubMed

Forsythe SD, Sasikumar S, Moaven O, et al. Personalized identification of the optimal HIPEC perfusion protocol in patient-derived tumor organoid platform. Ann Surg Oncol. 2020;27(13):4950–4960. https://doi.org/10.1245/s10434-020-08790-2.CrossRefPubMedPubMedCentral

Votanopoulos KI, Mazzocchi A, Sivakumar H, et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann Surg Oncol. 2019;26:139–47. https://doi.org/10.1245/s10434-018-7008-2.CrossRefPubMed

Radomski SN, Dunworth M, West JJ, et al. Intra- and interpatient drug response heterogeneity exist in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for non-gynecologic cancers. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-023-14696-6.CrossRefPubMed

Flood M, Narasimhan V, Wilson K, et al. Organoids as a robust preclinical model for precision medicine in colorectal cancer: a systematic review. Ann Surg Oncol. 2022;29(1):47–59. https://doi.org/10.1245/s10434-021-10829-x.CrossRefPubMed

Title: ASO Author Reflections: To Test or Not to Test: How Do We Decide the Optimal Site for Organoid Generation in Patients with Metastatic Disease?
Authors: Shannon N. Radomski, MD
Jonathan B. Greer, MD
Fabian M. Johnston, MD, MHS
Andrew J. Ewald, PhD
Publication date: 19-01-2024
Publisher: Springer International Publishing
Keyword: Gynecologic Cancer
Published in: Annals of Surgical Oncology / Issue 4/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-14887-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ASO Author Reflections: To Test or Not to Test: How Do We Decide the Optimal Site for Organoid Generation in Patients with Metastatic Disease?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2024

Modified Radical Neck Dissection for Papillary Thyroid Carcinoma via a Combined Endoscopy Approach: The Transoral Approach and the Chest Approach

ASO Visual Abstract: Characterizing the Immune Environment in Peritoneal Carcinomatosis—Insights for Novel Immunotherapy Strategies

ASO Author Reflections: A Novel Technique of Transaxillary Reverse-Sequence Endoscopic Nipple-Sparing Mastectomy and Direct-to-Implant Prepectoral Breast Reconstruction

Local Therapy Improves Survival for Early Recurrence After Resection of Colorectal Liver Metastases

ASO Author Reflections: Preoperative Imaging Findings to Predict Postoperative Pancreatic Fistula: Adding Another Tool to the Surgeon’s Toolbox

Clinical Outcomes of Transaxillary Reverse-Sequence Endoscopic Nipple-Sparing Mastectomy and Direct-to-Implant Prepectoral Breast Reconstruction: A Prospective Study of Initial 68 Procedures